Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline
Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board
VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci’s expanding pipeline of AI-designed therapeutics.
Dr. Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen.
“Ransi is a proven clinical leader, and we’re excited to have him join Absci at a moment when our AI-designed pipeline is rapidly advancing through clinical development,” said Sean McClain, Founder & CEO of Absci. “His wealth of experience will enhance our clinical development strategy and execution capabilities as we advance multiple programs, including our flagship ABS-201 program toward clinical proof of concept.”
A cardiologist and internist by training, Dr. Somaratne’s career is defined by work on multiple pioneering clinical development programs, including the Hemophilia A gene therapy Roctavian
“I am excited to join Absci at such a pivotal moment, when the AI Drug Creation Engine has already yielded multiple clinical-stage programs,” said Ransi Somaratne. “I look forward to advancing the development of a truly innovative pipeline of therapeutics with the potential to transform the lives of patients with significant unmet clinical need.”
Alongside Dr. Somaratne’s appointment, Absci announced the retirement of Professor Andreas Busch, Ph.D.. As Chief Innovation Officer, Professor Busch was a driving force in building Absci’s AI-designed therapeutics pipeline, most notably in the discovery and development of ABS-201. Professor Busch will transition from his executive duties on March 31, 2026 to co-chair Absci’s Scientific Advisory Board, where he will continue to provide scientific and strategic advice and oversight to the company.
“We are deeply grateful to Andreas for his immense contributions and leadership during a foundational period for Absci,” said Sean McClain, Founder and CEO. “His vision was the catalyst for our ABS-201 program. He leaves behind a legacy of innovation that will continue to guide our mission as we advance these potentially life-changing therapies through the clinic.”
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, Headline™ and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Media Contact:
[email protected]
Investor Contact:
Alex Khan
Corporate Vice President, Head of Investor Relations
[email protected]
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VALERO ENERGY CORP <VLO.N>: JEFFERIES CUTS TARGET PRICE TO $394 FROM $401
VALERO ENERGY CORP : JEFFERIES CUTS TARGET PRICE TO $394 FROM $401
Gold prices rise Rs 1,500/10g; silver up Rs 3,100/kg ahead of US economic data, softer yields. Buy, sell or hold?
The Shopify Stock Rally Isn't Done: Chart of the Week -- Barrons.com
By Doug Busch Shopify is no longer a pandemic-era growth story that simply failed to slow down. It is compounding at a pace few software platforms its size still manage. In the second quarter of 2026, sales on its platform rose 32%. That was the fifth straight quarter of growth exceeding 30%. Merchants are also using more of Shopify's own tools, from payments to Shop Pay, and new channels like AI shopping agents are starting to increase demand. The simple bull case is that the stock already commands a huge share of independent online commerce, and that position should become more valuable as more buying moves through its checkout. A rule of market mechanics is that the vast majority of an individual security's gain is driven by its underlying sector. Within technology, software has staged a robust recovery, joining semiconductors to power the broader sector higher. The iShares Expanded Tech-Software Sector ETF has maintained an upward trajectory since its mid-April lows, though the advance from $74 to $112 has been choppy as bulls repeatedly stepped in to defend when necessary. Breadth across large-cap software has expanded significantly, with 24 constituents surging over 20% over the past three months. During that same three-month window, Shopify generated outstanding relative strength, advancing 36%, more than doubling the IGV's 17% gain over the same period. Expect the stock's outperformance to persist as software momentum broadens. Let's examine the daily and monthly charts to outline the technical drivers behind this thesis. Looking at the daily chart, the ratio chart against the IGV shows persistent outperformance extending back to mid-May. The stock is riding an eight-session winning streak, during which price action cleared a double-bottom-with-handle pivot at $151.39. Within this broader base, the stock recorded a bullish golden cross in late August and successfully filled its Sept. 10 price gap, tracing back to its Aug. 4 session, the day before a powerful earnings reaction sent the stock surging 17% hi
Crypto prices
More
